Edition:
United States

Veru Inc (VERU.OQ)

VERU.OQ on NASDAQ Stock Exchange Capital Market

1.33USD
3:59pm EST
Change (% chg)

$-0.03 (-2.21%)
Prev Close
$1.36
Open
$1.36
Day's High
$1.36
Day's Low
$1.33
Volume
2,196
Avg. Vol
17,354
52-wk High
$2.37
52-wk Low
$0.90

Latest Key Developments (Source: Significant Developments)

Veru Announces Proposed Public Offering Of Common Stock
Wednesday, 26 Sep 2018 04:01pm EDT 

Sept 26 (Reuters) - Veru Inc ::VERU ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.VERU INC - IT INTENDS TO OFFER AND SELL, SUBJECT TO MARKET CONDITIONS, SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Veru Has Successful Pre-Ind Meeting With FDA For Veru-111 Next Generation Novel Oral Anti-Tubulin Therapy For Metastatic Prostate Cancer
Wednesday, 12 Sep 2018 08:00am EDT 

Sept 12 (Reuters) - Veru Inc ::VERU HAS SUCCESSFUL PRE-IND MEETING WITH FDA FOR VERU-111 NEXT GENERATION NOVEL ORAL ANTI-TUBULIN THERAPY FOR METASTATIC PROSTATE CANCER.VERU INC - FDA AGREED WITH VERU'S PLANS FOR A PHASE 1/2 CLINICAL TRIAL FOR VERU-111.VERU INC - EXPECT TO HAVE AN EARLY ASSESSMENT OF SAFETY AND EFFICACY OF VERU-111 BY EARLY PART OF 2019.VERU INC - FDA AGREED THAT AN IND FOR VERU-111 MAY BE SUBMITTED.  Full Article

Veru To Start Phase 2 Trial To Test Its Treatment For Side Effect Of Prostate Cancer Therapy
Tuesday, 12 Jun 2018 08:30am EDT 

June 12 (Reuters) - Veru Inc ::VERU TO START PHASE 2 TRIAL TO EVALUATE CIS-CLOMIPHENE CITRATE TO TREAT HOT FLASHES CAUSED BY ADVANCED PROSTATE CANCER THERAPY.VERU INC - SUBMISSION OF AN INVESTIGATIONAL NEW DRUG APPLICATION WITH U.S. FDA FOR VERU-944.VERU-EXPECT THIS SUMMER TO COMMENCE ENROLLING ABOUT 120 PATIENTS INTO PHASE 2 CLINICAL STUDY.VERU INC - U.S. PATENT ISSUED FOR VERU-944, EXPIRING 2035.  Full Article

Veru Inc - On Jan 4, 2018, Daniel Haines, CFO, Informed Co That He Was Resigning ‍​
Wednesday, 10 Jan 2018 05:08pm EST 

Jan 10 (Reuters) - Veru Inc ::VERU INC - ON JAN 4, 2018, DANIEL HAINES, CFO, INFORMED CO THAT HE WAS RESIGNING ‍​.VERU SAYS ‍HAINES' DUTIES AS CFO WERE ASSIGNED EFFECTIVE JAN 4, 2018 TO MICHELE GRECO​ - SEC FILING.  Full Article

Veru reports Q4 Loss Per Share $0.10
Tuesday, 2 Jan 2018 07:00am EST 

Jan 2 (Reuters) - Veru Inc ::VERU REPORTS FISCAL 2017 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.10.Q4 REVENUE $3.7 MILLION VERSUS $3.6 MILLION.  Full Article

Veru Acquires Novel Proprietary Formulation For Overactive Bladder
Monday, 11 Dec 2017 08:30am EST 

Dec 11 (Reuters) - Veru Inc ::VERU ACQUIRES NOVEL PROPRIETARY FORMULATION FOR OVERACTIVE BLADDER.VERU PLANS TO BEGIN SOLIFENACIN DRG BIOEQUIVALENCE STUDY IN 2018 AND TO FILE NDA IN 2019.‍UNDER TERMS OF AGREEMENT WITH CAMARGO, VERU PAID AN UNDISCLOSED UPFRONT FEE TO ACQUIRE ASSET​.UNDER TERMS, VERU TO PAY UNDISCLOSED MILESTONE FEES UPON SUCCESSFUL CLINICAL DEVELOPMENT, LOW SINGLE DIGIT ROYALTY UPON COMMERCIAL SALES​.FDA ‍CONFIRMED IN A MEETING WITH CO THAT REGULATORY APPROVAL FOR SOLIFENACIN DRG WILL REQUIRE A SINGLE BIOEQUIVALENCE STUDY​.  Full Article

Veru announces Tamsulosin drs bioequivalence clinical trial results
Monday, 13 Nov 2017 08:30am EST 

Nov 13 (Reuters) - Veru Inc :Veru announces Tamsulosin Drs bioequivalence clinical trial results.Veru Inc - ‍Expected timing of additional formulation adjustment should allow us to remain on track for a pre-NDA meeting in early 2018​.  Full Article

Veru files for mixed shelf of up to $50 million
Wednesday, 25 Oct 2017 05:49pm EDT 

Oct 25 (Reuters) - Veru Inc :Files for mixed shelf of up to $50 million - SEC filing‍​.  Full Article

FEMALE HEALTH COMPANY REPORTS Q1 LOSS PER SHARE $0.04
Thursday, 9 Feb 2017 06:15pm EST 

Female Health Co : THE FEMALE HEALTH COMPANY / VERU HEALTHCARE REPORTS FISCAL 2017 FIRST-QUARTER FINANCIAL RESULTS . Q1 LOSS PER SHARE $0.04 . Q1 REVENUE $3.2 MILLION . HAVE REQUESTED A PRE-IND MEETING WITH FDA FOR APP-944 . "MAY CONTINUE TO EXPERIENCE CHALLENGES FOR UNIT SALES OF FC2 IN GLOBAL PUBLIC SECTOR FOR REMAINDER OF FISCAL 2017" ."CURRENTLY SEEING PRESSURE ON SPENDING FOR FC2 BY LARGE GLOBAL AGENCIES AND DONOR GOVERNMENTS IN DEVELOPED WORLD".  Full Article

The Female Health Company/Veru Healthcare reports Q4 loss per share $0.06
Monday, 12 Dec 2016 08:30am EST 

Female Health Co : The Female Health Company/ Veru Healthcare reports fiscal 2016 fourth-quarter, full-year financial results . Q4 loss per share $0.06 .Q4 revenue $3.6 million.  Full Article